Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?

Jiralerspong S, Gonzalez-Angulo AM, Hung MC.

Cell Cycle. 2009 Sep 1;8(17):2681. Epub 2009 Sep 1. No abstract available.

PMID:
19717981
2.

Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.

Cell Cycle. 2009 Jul 1;8(13):2031-40. Epub 2009 Jul 21.

PMID:
19440038
3.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.

PMID:
22593441
4.

Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.

Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F.

Sci Rep. 2016 Jan 5;6:18673. doi: 10.1038/srep18673.

5.

Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.

Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z.

Mol Cell Biochem. 2014 Jan;386(1-2):63-71. doi: 10.1007/s11010-013-1845-x. Epub 2013 Oct 6.

PMID:
24096736
6.

Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG.

Br J Pharmacol. 2011 Mar;162(5):1096-108. doi: 10.1111/j.1476-5381.2010.01101.x.

7.

Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.

Thompson AM.

Clin Cancer Res. 2014 May 15;20(10):2508-15. doi: 10.1158/1078-0432.CCR-13-0354. Epub 2014 Mar 28.

8.

Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA.

Curr Mol Med. 2010 Oct;10(7):674-91.

PMID:
20712585
9.

Metabolic roles of AMPK and metformin in cancer cells.

Choi YK, Park KG.

Mol Cells. 2013 Oct;36(4):279-87. doi: 10.1007/s10059-013-0169-8. Epub 2013 Jun 19. Review.

10.

Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.

Guppy A, Jamal-Hanjani M, Pickering L.

Future Oncol. 2011 Jun;7(6):727-36. doi: 10.2217/fon.11.49. Review.

PMID:
21675836
11.

Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.

Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC, Zhang H.

Cell Death Dis. 2014 Feb 27;5:e1088. doi: 10.1038/cddis.2014.59.

12.

Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.

Wysocki PJ, Wierusz-Wysocka B.

Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22. Review.

PMID:
20465505
13.

Metformin: a therapeutic opportunity in breast cancer.

Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Review.

14.

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.

Hadad SM, Appleyard V, Thompson AM.

Breast Cancer Res Treat. 2009 Mar;114(2):391. doi: 10.1007/s10549-008-0016-3. Epub 2008 Apr 18. No abstract available.

PMID:
18421577
15.

Cracking open window of opportunity trials.

Kalinsky K, Hershman DL.

J Clin Oncol. 2012 Jul 20;30(21):2573-5. doi: 10.1200/JCO.2012.42.3293. Epub 2012 May 7. No abstract available.

PMID:
22565006
16.

Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S.

Horm Metab Res. 2013 May;45(5):387-90. doi: 10.1055/s-0032-1331204. Epub 2012 Dec 7.

PMID:
23225247
17.

EGF receptor in breast cancer chemoresistance.

Dickson RB, Deb TB.

Adv Exp Med Biol. 2007;608:113-8. Review. No abstract available.

PMID:
17993236
18.

Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.

Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB.

Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.

19.

Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.

Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, Feng G, Zou D, Wang H.

Clin Cancer Res. 2013 Oct 1;19(19):5372-80. doi: 10.1158/1078-0432.CCR-13-0203. Epub 2013 Aug 13.

20.

Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.

Hadad SM, Hardie DG, Appleyard V, Thompson AM.

Clin Transl Oncol. 2014 Aug;16(8):746-52. doi: 10.1007/s12094-013-1144-8. Epub 2013 Dec 12.

PMID:
24338509

Supplemental Content

Support Center